

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G80B826436A7EN.html>

Date: September 2026

Pages: 109

Price: US\$ 3,660.00 (Single User License)

ID: G80B826436A7EN

Abstracts

The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

United States market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors players cover Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the "Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Forecast" looks at past sales and reviews total world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Kirsten

Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales for 2026 through 2032. With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market by product type, application, key players and key regions and countries.

Segmentation by Type:

Direct Inhibitors

Signal transduction inhibitors

Segmentation by Application:

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Amgen

Mirati Therapeutics

Novartis

Genentech

Verastem Oncology

Revolution Medicines

Cardiff Oncology

Immuneering Corporation

Jacobio Pharmaceuticals

BridgeBio Pharma

Deciphera Pharmaceuticals

Elicio Therapeutics

InventisBio

Gritstone Bio

D3 Bio

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2021-2032)
 - 2.1.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Country/Region (2021, 2025 & 2032)
- 2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Type
 - 2.2.1 Direct Inhibitors
 - 2.2.2 Signal transduction inhibitors
 - 2.2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type
 - 2.2.3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
- 2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Segment by Application
 - 2.3.1 Retail Pharmacy
 - 2.3.2 Hospital Pharmacy
 - 2.3.3 Online Pharmacy
 - 2.3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application

2.3.4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.3.4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)

3 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET SIZE BY PLAYER

3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Player

3.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026)

3.1.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)

3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS BY REGION

4.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)

4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Revenue by Country/Region (2021-2026)

4.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)

4.4 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)

4.5 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)

4.6 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)

5.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)

5.3 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026)

6.2 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)

6.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026)

7.2 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)

7.3 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors by Region (2021-2026)

8.2 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026)

8.3 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS) INHIBITORS MARKET FORECAST

10.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)

10.1.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)

10.1.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.1.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.1.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.1.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.2 Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)

10.2.1 United States Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.2.2 Canada Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.2.3 Mexico Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.2.4 Brazil Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.3 APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)

10.3.1 China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Forecast

10.3.2 Japan Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.3.3 Korea Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.3.4 Southeast Asia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.3.5 India Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.3.6 Australia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Country (2027-2032)

10.4.1 Germany Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.4.2 France Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.4.3 UK Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.4.4 Italy Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.4.5 Russia Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.5 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Region (2027-2032)

10.5.1 Egypt Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.5.2 South Africa Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

Inhibitors Forecast

10.5.3 Israel Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.5.4 Turkey Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

10.6 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Type (2027-2032)

10.7 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast by Application (2027-2032)

10.7.1 GCC Countries Market Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecast

11 KEY PLAYERS ANALYSIS

11.1 Amgen

11.1.1 Amgen Company Information

11.1.2 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

11.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)

11.1.4 Amgen Main Business Overview

11.1.5 Amgen Latest Developments

11.2 Mirati Therapeutics

11.2.1 Mirati Therapeutics Company Information

11.2.2 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

11.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Mirati Therapeutics Main Business Overview

11.2.5 Mirati Therapeutics Latest Developments

11.3 Novartis

11.3.1 Novartis Company Information

11.3.2 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

11.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Novartis Main Business Overview

11.3.5 Novartis Latest Developments

11.4 Genentech

- 11.4.1 Genentech Company Information
- 11.4.2 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
- 11.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
- 11.4.4 Genentech Main Business Overview
- 11.4.5 Genentech Latest Developments
- 11.5 Verastem Oncology
- 11.5.1 Verastem Oncology Company Information
- 11.5.2 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
- 11.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
- 11.5.4 Verastem Oncology Main Business Overview
- 11.5.5 Verastem Oncology Latest Developments
- 11.6 Revolution Medicines
- 11.6.1 Revolution Medicines Company Information
- 11.6.2 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
- 11.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
- 11.6.4 Revolution Medicines Main Business Overview
- 11.6.5 Revolution Medicines Latest Developments
- 11.7 Cardiff Oncology
- 11.7.1 Cardiff Oncology Company Information
- 11.7.2 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
- 11.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
- 11.7.4 Cardiff Oncology Main Business Overview
- 11.7.5 Cardiff Oncology Latest Developments
- 11.8 Immuneering Corporation
- 11.8.1 Immuneering Corporation Company Information
- 11.8.2 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
- 11.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
- 11.8.4 Immuneering Corporation Main Business Overview
- 11.8.5 Immuneering Corporation Latest Developments

- 11.9 Jacobio Pharmaceuticals
 - 11.9.1 Jacobio Pharmaceuticals Company Information
 - 11.9.2 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
 - 11.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Jacobio Pharmaceuticals Main Business Overview
 - 11.9.5 Jacobio Pharmaceuticals Latest Developments
- 11.10 BridgeBio Pharma
 - 11.10.1 BridgeBio Pharma Company Information
 - 11.10.2 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
 - 11.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 BridgeBio Pharma Main Business Overview
 - 11.10.5 BridgeBio Pharma Latest Developments
- 11.11 Deciphera Pharmaceuticals
 - 11.11.1 Deciphera Pharmaceuticals Company Information
 - 11.11.2 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
 - 11.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 Deciphera Pharmaceuticals Main Business Overview
 - 11.11.5 Deciphera Pharmaceuticals Latest Developments
- 11.12 Elicio Therapeutics
 - 11.12.1 Elicio Therapeutics Company Information
 - 11.12.2 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
 - 11.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 Elicio Therapeutics Main Business Overview
 - 11.12.5 Elicio Therapeutics Latest Developments
- 11.13 InventisBio
 - 11.13.1 InventisBio Company Information
 - 11.13.2 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered
 - 11.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 InventisBio Main Business Overview

11.13.5 InventisBio Latest Developments

11.14 Gritstone Bio

11.14.1 Gritstone Bio Company Information

11.14.2 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Product Offered

11.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Revenue, Gross Margin and Market Share (2021-2026)

11.14.4 Gritstone Bio Main Business Overview

11.14.5 Gritstone Bio Latest Developments

11.15 D3 Bio

11.15.1 D3 Bio Company Information

11.15.2 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Product Offered

11.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors
Revenue, Gross Margin and Market Share (2021-2026)

11.15.4 D3 Bio Main Business Overview

11.15.5 D3 Bio Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)
- Table 2. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Direct Inhibitors
- Table 4. Major Players of Signal transduction inhibitors
- Table 5. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)
- Table 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & (\$ millions)
- Table 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)
- Table 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)
- Table 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & (\$ millions)
- Table 10. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)
- Table 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Player (2021-2026) & (\$ millions)
- Table 12. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player (2021-2026)
- Table 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Key Players Head office and Products Offered
- Table 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 15. New Products and Potential Entrants
- Table 16. Mergers & Acquisitions, Expansion
- Table 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & (\$ millions)
- Table 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)
- Table 19. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Country/Region (2021-2026) & (\$ millions)
- Table 20. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Revenue Market Share by Country/Region (2021-2026)

Table 21. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & (\$ millions)

Table 22. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)

Table 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & (\$ millions)

Table 24. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)

Table 25. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & (\$ millions)

Table 26. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)

Table 27. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & (\$ millions)

Table 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)

Table 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & (\$ millions)

Table 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & (\$ millions)

Table 31. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2021-2026) & (\$ millions)

Table 32. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country (2021-2026)

Table 33. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & (\$ millions)

Table 34. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & (\$ millions)

Table 35. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2021-2026) & (\$ millions)

Table 36. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2021-2026) & (\$ millions)

Table 37. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2021-2026) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Table 39. Key Market Challenges & Risks of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Table 40. Key Industry Trends of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Table 41. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 42. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Region (2027-2032)

Table 43. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 44. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 45. Amgen Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 46. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 47. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 48. Amgen Main Business

Table 49. Amgen Latest Developments

Table 50. Mirati Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 51. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 52. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 53. Mirati Therapeutics Main Business

Table 54. Mirati Therapeutics Latest Developments

Table 55. Novartis Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 56. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 57. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 58. Novartis Main Business

Table 59. Novartis Latest Developments

Table 60. Genentech Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 61. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 62. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. Genentech Main Business

Table 64. Genentech Latest Developments

Table 65. Verastem Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 66. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 67. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. Verastem Oncology Main Business

Table 69. Verastem Oncology Latest Developments

Table 70. Revolution Medicines Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 71. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 72. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 73. Revolution Medicines Main Business

Table 74. Revolution Medicines Latest Developments

Table 75. Cardiff Oncology Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 76. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 77. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Cardiff Oncology Main Business

Table 79. Cardiff Oncology Latest Developments

Table 80. Immuneering Corporation Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 81. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 82. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. Immuneering Corporation Main Business

Table 84. Immuneering Corporation Latest Developments

Table 85. Jacobio Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 86. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 87. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Jacobio Pharmaceuticals Main Business

Table 89. Jacobio Pharmaceuticals Latest Developments

Table 90. BridgeBio Pharma Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 91. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 92. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 93. BridgeBio Pharma Main Business

Table 94. BridgeBio Pharma Latest Developments

Table 95. Deciphera Pharmaceuticals Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 96. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 97. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. Deciphera Pharmaceuticals Main Business

Table 99. Deciphera Pharmaceuticals Latest Developments

Table 100. Elicio Therapeutics Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 101. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 102. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. Elicio Therapeutics Main Business

Table 104. Elicio Therapeutics Latest Developments

Table 105. InventisBio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 106. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 107. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 108. InventisBio Main Business

Table 109. InventisBio Latest Developments

Table 110. Gritstone Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 111. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

Inhibitors Product Offered

Table 112. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 113. Gritstone Bio Main Business

Table 114. Gritstone Bio Latest Developments

Table 115. D3 Bio Details, Company Type, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Area Served and Its Competitors

Table 116. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product Offered

Table 117. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 118. D3 Bio Main Business

Table 119. D3 Bio Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2025)

Figure 8. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type in 2025

Figure 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Retail Pharmacy

Figure 11. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Retail Pharmacy (2021-2026) & (\$ millions)

Figure 12. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Hospital Pharmacy

Figure 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Hospital Pharmacy (2021-2026) & (\$ millions)

Figure 14. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Online Pharmacy

Figure 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market: Online Pharmacy (2021-2026) & (\$ millions)

Figure 16. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application in 2025

Figure 17. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Player in 2025

Figure 18. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)

Figure 19. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 (\$ millions)

Figure 20. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 (\$ millions)

Figure 21. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2021-2026 (\$ millions)

Figure 23. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Value Market Share by Country in 2025

Figure 24. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region in 2025

Figure 29. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)

Figure 30. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)

Figure 31. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Country in 2025

Figure 38. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)

Figure 39. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors

Market Size Market Share by Application (2021-2026)

Figure 40. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 42. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 43. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 44. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share by Application (2021-2026)

Figure 48. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 49. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 50. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 51. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 52. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth 2021-2026 (\$ millions)

Figure 53. Americas Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 54. APAC Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 55. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 56. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 57. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 58. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 59. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 60. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 61. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 62. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 63. Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 65. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 66. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 67. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 68. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 69. UK Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 70. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 71. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 74. Israel Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size 2027-2032 (\$ millions)

Figure 76. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)

Inhibitors Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G80B826436A7EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G80B826436A7EN.html>